These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
703 related articles for article (PubMed ID: 27503452)
21. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Vollenweider FX; Kometer M Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121 [TBL] [Abstract][Full Text] [Related]
22. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Majić T; Schmidt TT; Gallinat J J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401 [TBL] [Abstract][Full Text] [Related]
23. Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. Sharma R; Batchelor R; Sin J J Psychoactive Drugs; 2023; 55(5):612-630. PubMed ID: 36933948 [TBL] [Abstract][Full Text] [Related]
24. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
25. Role of Psychedelics in Treatment-Resistant Depression. Kamal S; Jha MK; Radhakrishnan R Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346 [TBL] [Abstract][Full Text] [Related]
26. Psychedelics and Personality. Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323 [TBL] [Abstract][Full Text] [Related]
28. Psychedelia: The interplay of music and psychedelics. Jerotic K; Vuust P; Kringelbach ML Ann N Y Acad Sci; 2024 Jan; 1531(1):12-28. PubMed ID: 37983198 [TBL] [Abstract][Full Text] [Related]
29. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Kraehenmann R Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125 [TBL] [Abstract][Full Text] [Related]
30. Psychedelics in the treatment of unipolar mood disorders: a systematic review. Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684 [TBL] [Abstract][Full Text] [Related]
32. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952 [TBL] [Abstract][Full Text] [Related]
33. The Therapeutic Potential of Psilocybin. Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L Molecules; 2021 May; 26(10):. PubMed ID: 34063505 [TBL] [Abstract][Full Text] [Related]
34. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Bender D; Hellerstein DJ Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823 [TBL] [Abstract][Full Text] [Related]
35. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Romeo B; Hermand M; Pétillion A; Karila L; Benyamina A J Psychiatr Res; 2021 May; 137():273-282. PubMed ID: 33730602 [TBL] [Abstract][Full Text] [Related]
36. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. Kozlowska U; Nichols C; Wiatr K; Figiel M J Neurochem; 2022 Jul; 162(1):89-108. PubMed ID: 34519052 [TBL] [Abstract][Full Text] [Related]
37. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Barnett BS; Greer GR J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406 [TBL] [Abstract][Full Text] [Related]